EO 2401
Alternative Names: EO 2401Latest Information Update: 05 Dec 2025
At a glance
- Originator Enterome
- Class Antineoplastics; Bacterial vaccines; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Adrenocortical carcinoma; Glioblastoma; Phaeochromocytoma
- No development reported Solid tumours
Most Recent Events
- 02 Dec 2025 Updated efficacy data from phase Ib/IIa ROSALIE trial in Glioblastoma released by Enterome
- 02 Dec 2025 Enterome plans a randomized trial for Glioblastoma
- 12 Nov 2024 Enterome terminated a phase I/II trial in Adrenocortical carcinoma and Phaechromocytoma (Combination therapy, First-line therapy, Second-line therapy or greater, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Sweden, Denmark, USA (SC)due to strategic decision (NCT04187404)